	lowest tertile	mid tertile	highest tertile	p
Age at examination	66.2 (±9.9), N= 157	66.3 (±8.9), N=158	63.8 (±10.5), N=156	**0.040**
Age at onset	59.1 (±10.8), N=157	58.6 (±9.3), N=158	56.5 (±11.2), N=156	0.067
Disease duration	7.2 (±5.0), N=157	7.6 (±4.9), N=158	7.2 (±5.3), N=156	0.703
UPDRS III	26.0 (±10.5), N=149	27.1 (±13.3), N=149	25.0 (±10.3), N=144	0.285
MOCA	24.8 (±3.9), N=128	25.1 (±4.1), N=140	25.9 (±3.5), N=135	0.055
Prevalence of onset cognitive impairment	36/72 (50.0%)	43/89 (48.3%)	26/94 (27.7%)	**0.004**
BDI II	9.5 (±6.7), N=116	9.1 (±7.8), N=119	8.7 (±6.8), N=112	0.684
KL-VS haplotype	23/139 (16.5%)	28/139 (20.1%)	36/119 (30.3%)	**0.024**
beta-amyloid 1-42	700.1 (±280.6), N= 146	728.6 (±276.7), N=153	738.7 (±250.6), N=150	0.443
h-TAU	245.0 (±135.1), N=146	250.0 (±117.9), N=153	255.8 (±139.7), N=150	0.778
p-TAU	41.9 (±17.7), N=142	42.6 (±16.1), N=149	42.1 (±17.2), N=149	0.925
NfL	939.1 (±600.2), N=132	1050.6 (±1106.7), N=151	918.5 (±544.9), N=147	0.313
alpha-synuclein	589.8 (±315.0), N=149	637.8 (±293.5), N=154	614.5 (±287.5), N=141	0.377

Table 1: Demographic data in patients with Parkinson´s disease and levels of neurodegenerative proteins (in pg/ml) (**PD total cohort**) with stratification for lowest, middle and highest tertile of CSF-Klotho-levels. Analysis of variance (ANOVA) with significant p-values≤0.05 presented in bold letters. UPDRS III: Unified Parkinson`s Disease Rating Scale part III; MOCA: Montreal Cognitive Assessment; BDI II: Beck´s Depression Inventory. Post-hoc-Tests with adapted p-values according to Bonferroni were applied. For comparison of the prevalence of onset of cognitive impairment (MoCA≤25) during study and the prevalence of *KL-VS*-variant, chi-squared test was applied.